The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy

Kulasinghe, Arutha; Wu, Huawei; Warkiani, Majid Ebrahimi

doi:10.3390/mi9080397

Cited by 52 publications

(32 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One such approach is to use label-free selection with specific protein markers to select or to deplete those cells that express a particular marker. 47,81 Other approaches to CTC isolation rely on differences in their physical property and use techniques, such as filtration, chip technology, density gradient centrifugation, electric field, sound waves 82 and microfluidic technology. 54,[83][84][85] Characterisation of CTCs can be performed by using immunocytochemistry, molecular technologies and/or functional assays.…”

Section: Circulating Tumour Cells Ctcs and Metastasismentioning

confidence: 99%

Circulating biomarkers in patients with glioblastoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Gliomas are the most common tumours of the central nervous system and the most aggressive form is glioblastoma (GBM). Despite advances in treatment, patient survival remains low. GBM diagnosis typically relies on imaging techniques and postoperative pathological diagnosis; however, both procedures have their inherent limitations. Imaging modalities cannot differentiate tumour progression from treatment-related changes that mimic progression, known as pseudoprogression, which might lead to misinterpretation of therapy response and delay clinical interventions. In addition to imaging limitations, tissue biopsies are invasive and most of the time cannot be performed over the course of treatment to evaluate 'real-time' tumour dynamics. In an attempt to address these limitations, liquid biopsies have been proposed in the field. Blood sampling is a minimally invasive procedure for a patient to endure and could provide tumoural information to guide therapy. Tumours shed tumoural content, such as circulating tumour cells, cell-free nucleic acids, proteins and extracellular vesicles, into the circulation, and these biomarkers are reported to cross the blood-brain barrier. The use of liquid biopsies is emerging in the field of GBM. In this review, we aim to summarise the current literature on circulating biomarkers, namely circulating tumour cells, circulating tumour DNA and extracellular vesicles as potential non-invasively sampled biomarkers to manage the treatment of patients with GBM.

show abstract

Section: Circulating Tumour Cells Ctcs and Metastasismentioning

confidence: 99%

Circulating biomarkers in patients with glioblastoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…These platforms have grown in popularity due to their ability to automate laboratory functions and to integrate several laboratory functions onto a single chip. 8,31,43,74 Through innovations in micro-and nano-scale technology, these FIGURE 2. Structure and biomarkers of SARS-CoV-2 Virus.…”

Section: Lab-on-chip Biosensorsmentioning

confidence: 99%

Scalable COVID-19 Detection Enabled by Lab-on-Chip Biosensors

et al. 2020

View full text Add to dashboard Cite

Introduction-The emergence of a novel coronavirus, SARS-CoV-2, has highlighted the need for rapid, accurate, and point-of-care diagnostic testing. As of now, there is not enough testing capacity in the world to meet the stated testing targets, which are expected to skyrocket globally for broader testing during reopening Aim-This review focuses on the development of lab-on-chip biosensing platforms for diagnosis of COVID-19 infection. Results-We discuss advantages of utilizing lab-on-chip technologies in response to the current global pandemic, including their potential for low-cost, rapid sample-toanswer processing times, and ease of integration into a range of healthcare settings. We then highlight the development of magnetic, colorimetric, plasmonic, electrical, and lateral flow-based lab-on-chip technologies for the detection of SARS-CoV-2, in addition to other viruses. We focus on rapid, point-of-care technologies that can be deployed at scale, as such devices could be promising alternatives to the current gold standard of reverse transcription-polymerase chain reaction (RT-PCR) diagnostic testing. Conclusion-This review is intended to provide an overview of the current state-of-the-field and serve as a resource for innovative development of new lab-on-chip assays for COVID-19 detection.

show abstract

“…Microfluidic devices focused on CTCs analysis include cellular segregation and examination, demonstrating high efficiency, reactivity and selectivity; low sample amount and reagent costs; and high liquid control capacity [32]. Most of the studies showed the development of microfluidic chips for CTCs capture using the affinity towards a specific cell membrane protein called "Epithelial Cell Adhesion Molecule" (EpCAM) [33]. This capture is achieved by the immobilization in the channels of the microfluidic system of specific antibodies against this EpCAM protein.…”

Section: Platforms Based On Circulating Tumor Cells Analysismentioning

confidence: 99%

Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer

Sierra

Marrugo-Ramírez

Rodriguez-Trujíllo

et al. 2020

Sensors

View full text Add to dashboard Cite

Cancer represents one of the conditions with the most causes of death worldwide. Common methods for its diagnosis are based on tissue biopsies—the extraction of tissue from the primary tumor, which is used for its histological analysis. However, this technique represents a risk for the patient, along with being expensive and time-consuming and so it cannot be frequently used to follow the progress of the disease. Liquid biopsy is a new cancer diagnostic alternative, which allows the analysis of the molecular information of the solid tumors via a body fluid draw. This fluid-based diagnostic method displays relevant advantages, including its minimal invasiveness, lower risk, use as often as required, it can be analyzed with the use of microfluidic-based platforms with low consumption of reagent, and it does not require specialized personnel and expensive equipment for the diagnosis. In recent years, the integration of sensors in microfluidics lab-on-a-chip devices was performed for liquid biopsies applications, granting significant advantages in the separation and detection of circulating tumor nucleic acids (ctNAs), circulating tumor cells (CTCs) and exosomes. The improvements in isolation and detection technologies offer increasingly sensitive and selective equipment’s, and the integration in microfluidic devices provides a better characterization and analysis of these biomarkers. These fully integrated systems will facilitate the generation of fully automatized platforms at low-cost for compact cancer diagnosis systems at an early stage and for the prediction and prognosis of cancer treatment through the biomarkers for personalized tumor analysis.

show abstract

The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy

Cited by 52 publications

References 118 publications

Circulating biomarkers in patients with glioblastoma

Circulating biomarkers in patients with glioblastoma

Scalable COVID-19 Detection Enabled by Lab-on-Chip Biosensors

Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer

Contact Info

Product

Resources

About